Q2 2023 · 13F-HR
ARCH Venture Management, LLCholdings as filed
Filed 2023-08-09 · accession 0001012975-23-000327
$162.0M
Reported value
6
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 26886C107 | — | EQRX, INC. | $67.6M | 41.7% | 36,335,375 | Common | NONE |
| 92539P101 | — | VERVE THERAPEUTICS, INC. | $37.7M | 23.3% | 2,008,809 | Common | NONE |
| 29479A108 | ERAS | ERASCA, INC. | $30.5M | 18.8% | 11,055,554 | Common | NONE |
| 24823R105 | DNLI | DENALI THERAPEUTICS, INC. | $20.5M | 12.6% | 693,749 | Common | NONE |
| 82933R100 | — | SINGULAR GENOMICS SYSTEMS, INC. | $3.2M | 1.95% | 3,798,926 | Common | NONE |
| 91381U200 | UNBX | UNITY BIOTECHNOLOGY, INC. | $2.6M | 1.58% | 1,004,817 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.